Description du projet
Des sondes spécifiques aux glycanes pour la détection des formes précoces de cancer
Le développement du cancer est un processus en plusieurs étapes et la découverte de la tumeur à un stade précoce, lorsque le cancer est encore curable, exige des outils de diagnostic sensibles et efficaces. Le projet GlycoImaging, financé par le programme Actions Marie Skłodowska-Curie, entend concevoir et mettre en œuvre de nouveaux tests de détection des glycanes en tant que biomarqueurs associés aux cancers métastatiques agressifs dans le sang, l’urine, les cellules et les tissus. Le projet comprendra la formation de huit spécialistes de la recherche en début de carrière par un consortium composé de six partenaires du monde universitaire et de l’industrie ayant des compétences en biomédecine, en imagerie et en synthèse des particules. L’objectif du projet est de jeter les bases d’un programme interdisciplinaire d’enseignement et de formation à la recherche de haute qualité.
Objectif
The overall objective of Glyco Imaging is to develop novel assays for detection of glycans as biomarkers associated with aggressive and metastatic cancer forms. The assays will be developed for biomarker detection in blood, urine, cells and tissue. Molecularly Imprinted Polymers (MIPs), or plastic antibodies, have been developed for targeting the human glycan sialic acid (SA), or Neu5Ac. The efficiency of the Neu5Ac specific SAMIPs targeted to the biomarker SA in different solvents (methanol, water, phosphate buffer) will be exploited. The non-human Neu5Gc, which is incorporated into human glycoconjugates through dietary sources such as red meat, and shown to be involved in malignant cell transformation in humans, will also be investigated by using highly specific Neu5Gc-SAMIPs. The imaging and detection techniques used will be based on fluorescence, 3D-viewing of cancer cells by digital holographic microscopy and magnetic separation columns.
The results in this research consortium will lead to major technological advances having impact on 1) health care, since it will develop more accurate and reliable diagnostics of aggressive and metastatic cancers, 2) drug discovery allowing a faster and cheaper biomarker targeting and detection; and 3) biochemistry research laboratories in resulting in improved understanding of glycan expression in cancer, with emphasis on aggressive metastatic cancer. The training of researchers will be performed by a consortium consisting of 6 partners with biomedical, imaging and particle synthesis skills (4 groups, one institution, one technology company). This forms the basis for a very competent interdisciplinary training program with high quality in both education and research.
8 early stage researchers (ESRs) working on specific tasks within 5 work packages will follow a rich training program providing a well-balanced spectrum of scientific, business and entrepreneurial skills.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesphysical sciencesopticsmicroscopy
- natural sciencesbiological sciencesbiochemistrybiomoleculescarbohydrates
- medical and health sciencesclinical medicineoncology
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
Programme(s)
Régime de financement
MSCA-ITN-ETN - European Training NetworksCoordinateur
205 06 Malmoe
Suède